Amgen Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Amgen Inc. (AMGN) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$908.00 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-12.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2020-02-12
- Amgen Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-03-31 was $413.00M, a 93.05% decline year-over-year.
- Amgen Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was -$5.01B, a 726.38% decline year-over-year.
- Amgen Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was $1.82B, a 391.91% increase year-over-year.
- Amgen Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-06-30 was $390.00M.
- Amgen Inc. cash and cash equivalents, period increase (decrease) for fiscal 2019 was -$908.00M, a 128.87% decline from fiscal 2018.
- Amgen Inc. cash and cash equivalents, period increase (decrease) for fiscal 2018 was $3.15B, a 462.61% increase from fiscal 2017.
- Amgen Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $559.00M.
- Amgen Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$903.00M, a 318.64% decline from fiscal 2015.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2019-12-31 | -$908.00M 10-K · filed 2020-02-12 | |||
| 2019-03-31 | $413.00M 10-Q · filed 2019-05-01 | -$4.60B derived: sum of 2 quarters · filed 2020-02-12 | -$2.77B derived: sum of 3 quarters · filed 2020-02-12 | -$2.38B derived: sum of 4 quarters · filed 2020-02-12 |
| 2018-12-31 | -$5.01B derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-12 | -$3.19B derived: sum of 2 quarters · filed 2020-02-12 | -$2.80B derived: sum of 3 quarters · filed 2020-02-12 | $3.15B 10-K · filed 2020-02-12 |
| 2018-09-30 | $1.82B derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | $2.21B derived: sum of 2 quarters · filed 2018-10-31 | $8.16B 10-Q · filed 2018-10-31 | $8.96B derived: sum of 4 quarters · filed 2020-02-12 |
| 2018-06-30 | $390.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-27 | $6.33B 10-Q · filed 2018-07-27 | $7.13B derived: sum of 3 quarters · filed 2020-02-12 | $7.50B derived: sum of 4 quarters · filed 2020-02-12 |
| 2018-03-31 | $5.94B 10-Q · filed 2019-05-01 | $6.74B derived: sum of 2 quarters · filed 2020-02-12 | $7.11B derived: sum of 3 quarters · filed 2020-02-12 | $6.38B derived: sum of 4 quarters · filed 2020-02-12 |
| 2017-12-31 | $800.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-12 | $1.17B derived: sum of 2 quarters · filed 2020-02-12 | $442.00M derived: sum of 3 quarters · filed 2020-02-12 | $559.00M 10-K · filed 2020-02-12 |
| 2017-09-30 | $371.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | -$358.00M derived: sum of 2 quarters · filed 2018-10-31 | -$241.00M 10-Q · filed 2018-10-31 | -$485.00M derived: sum of 4 quarters · filed 2019-02-13 |
| 2017-06-30 | -$729.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-27 | -$612.00M 10-Q · filed 2018-07-27 | -$856.00M derived: sum of 3 quarters · filed 2019-02-13 | -$1.00M derived: sum of 4 quarters · filed 2019-02-13 |
| 2017-03-31 | $117.00M 10-Q · filed 2018-04-25 | -$127.00M derived: sum of 2 quarters · filed 2019-02-13 | $728.00M derived: sum of 3 quarters · filed 2019-02-13 | $462.00M derived: sum of 4 quarters · filed 2019-02-13 |
| 2016-12-31 | -$244.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-13 | $611.00M derived: sum of 2 quarters · filed 2019-02-13 | $345.00M derived: sum of 3 quarters · filed 2019-02-13 | -$903.00M 10-K · filed 2019-02-13 |
| 2016-09-30 | $855.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-26 | $589.00M derived: sum of 2 quarters · filed 2017-10-26 | -$659.00M 10-Q · filed 2017-10-26 | $259.00M derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-06-30 | -$266.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-26 | -$1.51B 10-Q · filed 2017-07-26 | -$596.00M derived: sum of 3 quarters · filed 2018-02-13 | -$1.17B derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-03-31 | -$1.25B 10-Q · filed 2017-04-27 | -$330.00M derived: sum of 2 quarters · filed 2018-02-13 | -$899.00M derived: sum of 3 quarters · filed 2018-02-13 | $32.00M derived: sum of 4 quarters · filed 2018-02-13 |
| 2015-12-31 | $918.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $349.00M derived: sum of 2 quarters · filed 2018-02-13 | $1.28B derived: sum of 3 quarters · filed 2018-02-13 | $413.00M 10-K · filed 2018-02-13 |
| 2015-09-30 | -$569.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-28 | $362.00M derived: sum of 2 quarters · filed 2016-10-28 | -$505.00M 10-Q · filed 2016-10-28 | -$451.00M derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-06-30 | $931.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-29 | $64.00M 10-Q · filed 2016-07-29 | $118.00M derived: sum of 3 quarters · filed 2017-02-14 | -$557.00M derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-03-31 | -$867.00M 10-Q · filed 2016-05-02 | -$813.00M derived: sum of 2 quarters · filed 2017-02-14 | -$1.49B derived: sum of 3 quarters · filed 2017-02-14 | -$823.00M derived: sum of 4 quarters · filed 2017-02-14 |
| 2014-12-31 | $54.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-14 | -$621.00M derived: sum of 2 quarters · filed 2017-02-14 | $44.00M derived: sum of 3 quarters · filed 2017-02-14 | -$74.00M 10-K · filed 2017-02-14 |
| 2014-09-30 | -$675.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-02 | -$10.00M derived: sum of 2 quarters · filed 2015-11-02 | -$128.00M 10-Q · filed 2015-11-02 | -$4.60B derived: sum of 4 quarters · filed 2016-10-31 |
| 2014-06-30 | $665.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $547.00M 10-Q · filed 2015-08-05 | -$3.93B derived: sum of 3 quarters · filed 2016-10-31 | -$1.45B derived: sum of 4 quarters · filed 2016-10-31 |
| 2014-03-31 | -$118.00M 10-Q · filed 2015-04-27 | -$4.59B derived: sum of 2 quarters · filed 2016-10-31 | -$2.12B derived: sum of 3 quarters · filed 2016-10-31 | $1.16B derived: sum of 4 quarters · filed 2016-10-31 |
| 2013-12-31 | -$4.48B derived: 8-K 12 month − 10-Q 9 month · filed 2016-10-31 | -$2.00B derived: sum of 2 quarters · filed 2016-10-31 | $1.27B derived: sum of 3 quarters · filed 2016-10-31 | $548.00M 8-K · filed 2016-10-31 |
| 2013-09-30 | $2.48B derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-29 | $5.75B derived: sum of 2 quarters · filed 2014-10-29 | $5.02B 10-Q · filed 2014-10-29 | $2.46B derived: sum of 4 quarters · filed 2015-02-19 |
| 2013-06-30 | $3.28B derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | $2.55B 10-Q · filed 2014-08-05 | -$17.00M derived: sum of 3 quarters · filed 2015-02-19 | -$43.00M derived: sum of 4 quarters · filed 2015-02-19 |
| 2013-03-31 | -$727.00M 10-Q · filed 2014-04-30 | -$3.29B derived: sum of 2 quarters · filed 2015-02-19 | -$3.32B derived: sum of 3 quarters · filed 2015-02-19 | -$1.68B derived: sum of 4 quarters · filed 2015-02-19 |
| 2012-12-31 | -$2.57B derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-19 | -$2.59B derived: sum of 2 quarters · filed 2015-02-19 | -$950.00M derived: sum of 3 quarters · filed 2015-02-19 | -$3.69B 10-K · filed 2015-02-19 |
| 2012-09-30 | -$26.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-29 | $1.62B derived: sum of 2 quarters · filed 2013-10-29 | -$1.12B 10-Q · filed 2013-10-29 | $1.93B derived: sum of 4 quarters · filed 2014-02-24 |
| 2012-06-30 | $1.64B derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | -$1.10B 10-Q · filed 2013-08-06 | $1.96B derived: sum of 3 quarters · filed 2014-02-24 | -$149.00M derived: sum of 4 quarters · filed 2014-02-24 |
| 2012-03-31 | -$2.74B 10-Q · filed 2013-05-03 | $316.00M derived: sum of 2 quarters · filed 2014-02-24 | -$1.79B derived: sum of 3 quarters · filed 2014-02-24 | $2.94B derived: sum of 4 quarters · filed 2014-02-24 |
| 2011-12-31 | $3.06B derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-24 | $948.00M derived: sum of 2 quarters · filed 2014-02-24 | $5.68B derived: sum of 3 quarters · filed 2014-02-24 | $3.66B 10-K · filed 2014-02-24 |
| 2011-09-30 | -$2.11B derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | $2.63B derived: sum of 2 quarters · filed 2012-11-06 | $604.00M 10-Q · filed 2012-11-06 | $940.00M derived: sum of 4 quarters · filed 2013-02-27 |
| 2011-06-30 | $4.73B derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-08 | $2.71B 10-Q · filed 2012-08-08 | $3.05B derived: sum of 3 quarters · filed 2013-02-27 | $4.29B derived: sum of 4 quarters · filed 2013-02-27 |
| 2011-03-31 | -$2.02B 10-Q · filed 2012-05-08 | -$1.69B derived: sum of 2 quarters · filed 2013-02-27 | -$446.00M derived: sum of 3 quarters · filed 2013-02-27 | -$1.00B derived: sum of 4 quarters · filed 2013-02-27 |
| 2010-12-31 | $336.00M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27 | $1.57B derived: sum of 2 quarters · filed 2013-02-27 | $1.02B derived: sum of 3 quarters · filed 2013-02-27 | $403.00M 10-K · filed 2013-02-27 |
| 2010-09-30 | $1.24B derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $685.00M derived: sum of 2 quarters · filed 2011-11-04 | $67.00M 10-Q · filed 2011-11-04 | -$626.00M derived: sum of 4 quarters · filed 2012-02-29 |
| 2010-06-30 | -$554.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-08 | -$1.17B 10-Q · filed 2011-08-08 | -$1.86B derived: sum of 3 quarters · filed 2012-02-29 | -$1.26B derived: sum of 4 quarters · filed 2012-02-29 |
| 2010-03-31 | -$618.00M 10-Q · filed 2011-05-10 | -$1.31B derived: sum of 2 quarters · filed 2012-02-29 | -$702.00M derived: sum of 3 quarters · filed 2012-02-29 | -$511.00M derived: sum of 4 quarters · filed 2012-02-29 |
| 2009-12-31 | -$693.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | -$84.00M derived: sum of 2 quarters · filed 2012-02-29 | $107.00M derived: sum of 3 quarters · filed 2012-02-29 | $1.11B 10-K · filed 2012-02-29 |
| 2009-09-30 | $609.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-08 | $800.00M derived: sum of 2 quarters · filed 2010-11-08 | $1.80B 10-Q · filed 2010-11-08 | $1.05B derived: sum of 4 quarters · filed 2011-02-25 |
| 2009-06-30 | $191.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2010-08-09 | $1.19B 10-Q · filed 2010-08-09 | $446.00M derived: sum of 3 quarters · filed 2011-02-25 | -$424.00M derived: sum of 4 quarters · filed 2011-02-25 |
| 2009-03-31 | $1.00B 10-Q · filed 2010-05-07 | $255.00M derived: sum of 2 quarters · filed 2011-02-25 | -$615.00M derived: sum of 3 quarters · filed 2011-02-25 | |
| 2008-12-31 | -$748.00M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-25 | -$1.62B derived: sum of 2 quarters · filed 2011-02-25 | -$250.00M 10-K · filed 2011-02-25 | |
| 2008-09-30 | -$870.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2009-11-06 | $498.00M 10-Q · filed 2009-11-06 | ||
| 2008-06-30 | $1.37B 10-Q · filed 2009-08-10 | |||
| 2007-12-31 | $741.00M 10-K · filed 2010-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |